 |
66 Companies | 59 Products |
|
|
59 Products | |
344 Diseases | |
313 Trials |  |
11771 News |  |
| «12...209210211212213214215216217218219220221» |
- Piqray (alpelisib) / Novartis
Trial primary completion date, Combination therapy, Stroma: A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients (clinicaltrials.gov) - May 18, 2014
P1, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2014 --> Jul 2015
- Piqray (alpelisib) / Novartis
Trial completion date, Combination therapy, Stroma: A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients (clinicaltrials.gov) - May 18, 2014
P1, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2014 --> Jul 2015 Trial completion date: Mar 2016 --> Jul 2015
- WX-554 / Heidelberg Pharma, WX-037 / Heidelberg Pharma
P1 data, Trial primary completion date, Combination therapy: Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours (clinicaltrials.gov) - May 14, 2014
P1, N=13, Terminated, Sponsor: Wilex
Trial completion date: Mar 2016 --> Jul 2015 Trial primary completion date: Mar 2015 --> Apr 2014
- WX-554 / Heidelberg Pharma, WX-037 / Heidelberg Pharma
P1 data, Trial termination, Combination therapy: Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours (clinicaltrials.gov) - May 14, 2014
P1, N=13, Terminated, Sponsor: Wilex
Trial primary completion date: Mar 2015 --> Apr 2014 Recruiting --> Terminated; Study terminated for business reasons
- WX-554 / Heidelberg Pharma, WX-037 / Heidelberg Pharma
P1 data, Trial completion date, Combination therapy: Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours (clinicaltrials.gov) - May 14, 2014
P1, N=13, Terminated, Sponsor: Wilex
Recruiting --> Terminated; Study terminated for business reasons Trial completion date: Jun 2015 --> Apr 2014
- WX-554 / Heidelberg Pharma, WX-037 / Heidelberg Pharma
P1 data, Enrollment change, Combination therapy: Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours (clinicaltrials.gov) - May 14, 2014
P1, N=13, Terminated, Sponsor: Wilex
Trial completion date: Jun 2015 --> Apr 2014 N=100 --> 13
- | buparlisib (AN2025) / Novartis, Adlai Nortye
Trial completion: Pharmacodynamic Study of BKM120 in Breast Cancer (clinicaltrials.gov) - Mar 31, 2014
P0, N=20, Completed, Sponsor: Sofia Perea, Director Clinical Trials Unit.
N=100 --> 13 Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, buparlisib (AN2025) / Novartis, Adlai Nortye
Biomarker, Enrollment open, Combination therapy, Metastases: PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Mar 10, 2014
P1/2, N=30, Recruiting, Sponsor: University of Chicago
Recruiting --> Completed Not yet recruiting --> Recruiting
- || refametinib (BAY86-9766) / Bayer, Aliqopa (copanlisib) / Bayer
Enrollment closed, Metastases: Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer (clinicaltrials.gov) - Feb 24, 2014
P1, N=92, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- buparlisib (AN2025) / Novartis, Adlai Nortye, dactolisib (RTB101) / Adicet Bio
Trial completion, Combination therapy, Metastases: PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer (clinicaltrials.gov) - Feb 13, 2014
P1, N=72, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- pictilisib (GDC-0941) / Roche
Enrollment open, Combination therapy, Metastases: GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer (clinicaltrials.gov) - Feb 9, 2014
P1/2, N=120, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Aliqopa (copanlisib) / Bayer
Enrollment closed, Combination therapy, Metastases: Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer (clinicaltrials.gov) - Jan 19, 2014
P1, N=60, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || pimasertib (AS703026) / Day One Biopharma
Enrollment closed, Combination therapy, Metastases: EMR 200066-006: Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Nov 11, 2013
P1, N=170, Active, not recruiting, Sponsor: EMD Serono
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- buparlisib (AN2025) / Novartis, Adlai Nortye
Trial initiation date, Combination therapy: NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer (clinicaltrials.gov) - Oct 6, 2013
P2, N=220, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Initiation date: Mar 2013 --> Sep 2013
- buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment open, Combination therapy: NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer (clinicaltrials.gov) - Oct 6, 2013
P2, N=220, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Mar 2013 --> Sep 2013 Not yet recruiting --> Recruiting
- ||| WX-554 / Heidelberg Pharma, WX-037 / Heidelberg Pharma
Enrollment open, P1 data, Combination therapy: Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours (clinicaltrials.gov) - Aug 6, 2013
P1, N=100, Recruiting, Sponsor: Wilex
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | pictilisib (GDC-0941) / Roche
New P1/2 trial, Combination therapy, Metastases: GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer (clinicaltrials.gov) - Aug 5, 2013
P1/2, N=120, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
- buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment open, Combination therapy, Metastases: PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 24, 2013
P1, N=39, Recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| serabelisib (MLN1117) / Takeda
New P1 trial, Combination therapy, Metastases: A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies (clinicaltrials.gov) - Jul 11, 2013
P1, N=152, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
- | SF1126 / SignalRx
Trial completion, Metastases: A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors (clinicaltrials.gov) - Jun 10, 2013
P1, N=44, Completed, Sponsor: Semafore Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| WX-554 / Heidelberg Pharma, WX-037 / Heidelberg Pharma
New P1 trial, P1 data, Combination therapy: Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours (clinicaltrials.gov) - May 19, 2013
P1, N=100, Recruiting, Sponsor: Wilex
- | buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment open: Neoadjuvant BKM120 in High-risk Prostate Cancer (clinicaltrials.gov) - May 14, 2013
P2, N=24, Recruiting, Sponsor: Phillip Febbo
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Aliqopa (copanlisib) / Bayer
Enrollment change: CHRONOS-1: Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas (clinicaltrials.gov) - Apr 29, 2013
P2, N=180, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting N=60 --> 180
- Piqray (alpelisib) / Novartis
Enrollment open, Combination therapy, Stroma: A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients (clinicaltrials.gov) - Apr 8, 2013
P1, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
N=60 --> 180 Not yet recruiting --> Recruiting
- Piqray (alpelisib) / Novartis
Enrollment open, Combination therapy, Metastases: BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Apr 4, 2013
P1, N=30, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment open: Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 1, 2013
P=N/A, N=18, Recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | buparlisib (AN2025) / Novartis, Adlai Nortye
New P2 trial, Combination therapy: NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer (clinicaltrials.gov) - Mar 20, 2013
P2, N=220, Recruiting, Sponsor: Novartis Pharmaceuticals
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, buparlisib (AN2025) / Novartis, Adlai Nortye
Biomarker, New P1/2 trial, Combination therapy, Metastases: PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Mar 20, 2013
P1/2, N=30, Recruiting, Sponsor: University of Chicago
- buparlisib (AN2025) / Novartis, Adlai Nortye
New P2 trial: BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy (clinicaltrials.gov) - Mar 5, 2013
P2, N=41, Recruiting, Sponsor: Prince of Songkla University
- Piqray (alpelisib) / Novartis
New P1 trial, Combination therapy, Metastases: BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Feb 13, 2013
P1, N=30, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Not yet recruiting --> Recruiting .
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment open, Monotherapy, Metastases: PIK-ORL: Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive (clinicaltrials.gov) - Jan 27, 2013
P2, N=70, Recruiting, Sponsor: Centre Leon Berard
. Not yet recruiting --> Recruiting
- Piqray (alpelisib) / Novartis
Trial initiation date, Combination therapy, Metastases: PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Jan 15, 2013
P1, N=41, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Initiation date: Sep 2012 --> Dec 2012
- Piqray (alpelisib) / Novartis
Enrollment open, Combination therapy, Metastases: PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Jan 15, 2013
P1, N=41, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Sep 2012 --> Dec 2012 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, buparlisib (AN2025) / Novartis, Adlai Nortye
New P2 trial, Monotherapy, Metastases: PIK-ORL: Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive (clinicaltrials.gov) - Nov 27, 2012
P2, N=70, Recruiting, Sponsor: Centre Leon Berard
- | Piqray (alpelisib) / Novartis
New P1 trial, Combination therapy, Stroma: A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients (clinicaltrials.gov) - Nov 26, 2012
P1, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
- |||| Aliqopa (copanlisib) / Bayer
Enrollment open: CHRONOS-1: Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas (clinicaltrials.gov) - Nov 21, 2012
P2, N=180, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- buparlisib (AN2025) / Novartis, Adlai Nortye
New P1 trial, Combination therapy, Metastases: PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 6, 2012
P1, N=39, Recruiting, Sponsor: City of Hope Medical Center
- buparlisib (AN2025) / Novartis, Adlai Nortye
Trial initiation date: Pharmacodynamic Study of BKM120 in Breast Cancer (clinicaltrials.gov) - Oct 22, 2012
P0, N=20, Completed, Sponsor: Sofia Perea, Director Clinical Trials Unit.
Not yet recruiting --> Recruiting Initiation date: Jan 2012 --> Oct 2012
- | buparlisib (AN2025) / Novartis, Adlai Nortye
New P2 trial: Neoadjuvant BKM120 in High-risk Prostate Cancer (clinicaltrials.gov) - Sep 26, 2012
P2, N=24, Recruiting, Sponsor: Phillip Febbo
- DFN-529 / Diffusion Pharma
Enrollment change, Metastases: P52901: Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Sep 19, 2012
P1, N=13, Completed, Sponsor: Paloma Pharmaceuticals, Inc.
Initiation date: Jan 2012 --> Oct 2012 N=33 --> 13
- | DFN-529 / Diffusion Pharma
Trial completion, Metastases: P52901: Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Sep 19, 2012
P1, N=13, Completed, Sponsor: Paloma Pharmaceuticals, Inc.
N=33 --> 13 Recruiting --> Completed
- ||||| Aliqopa (copanlisib) / Bayer
New P2 trial: CHRONOS-1: Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas (clinicaltrials.gov) - Aug 6, 2012
P2, N=180, Recruiting, Sponsor: Bayer
- Aliqopa (copanlisib) / Bayer
Trial completion, Monotherapy, Metastases: Japanese BAY80-6946 Monotherapy Phase I Study (clinicaltrials.gov) - Jul 22, 2012
P1, N=10, Completed, Sponsor: Bayer
Recruiting --> Completed Active, not recruiting --> Completed
- buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment open, Combination therapy, Metastases: BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer (clinicaltrials.gov) - Jul 18, 2012
P1, N=22, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment open, Metastases: SOLTI-1103: A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer (clinicaltrials.gov) - Jul 1, 2012
P2, N=50, Recruiting, Sponsor: SOLTI Breast Cancer Research Group
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- buparlisib (AN2025) / Novartis, Adlai Nortye
New P2 trial, Metastases: SOLTI-1103: A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer (clinicaltrials.gov) - Jun 25, 2012
P2, N=50, Recruiting, Sponsor: SOLTI Breast Cancer Research Group
- buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment open, Combination therapy, Surgery, Metastases: PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic (clinicaltrials.gov) - Jun 14, 2012
P1, N=32, Recruiting, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Piqray (alpelisib) / Novartis
New P1 trial, Combination therapy, Metastases: PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Jun 5, 2012
P1, N=41, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||| everolimus / Generic mfg., paclitaxel / Generic mfg.
Enrollment change: NCI-2012-01514: Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer (clinicaltrials.gov) - Apr 26, 2012
P2, N=62, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting N=50 --> 62
- |||| everolimus / Generic mfg., paclitaxel / Generic mfg.
Trial completion: NCI-2012-01514: Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer (clinicaltrials.gov) - Apr 26, 2012
P2, N=62, Completed, Sponsor: M.D. Anderson Cancer Center
N=50 --> 62 Active, not recruiting --> Completed